Dapagliflozin vs Empagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00528372 · Phase 3 · completed

The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)

Result source: NCT01392677

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01131676 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).

Next expected readout: November 2026 · NCT05057806 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)

Result source: NCT01131676

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapagliflozinEmpagliflozin
HbA1c, change-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
Body weight, change (kg)-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003
HbA1c below 7%50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
Fasting plasma glucose, change-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
3-point MACE (% with event)—Not posted · NCT0417099810.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676

HbA1c, change

Dapagliflozin
-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
Empagliflozin
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297

Body weight, change (kg)

Dapagliflozin
-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
Empagliflozin
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003

HbA1c below 7%

Dapagliflozin
50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
Empagliflozin
34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543

Fasting plasma glucose, change

Dapagliflozin
-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
Empagliflozin
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297

3-point MACE (% with event)

Dapagliflozin
—Not posted · NCT04170998
Empagliflozin
10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Dapagliflozin: 9 of 9 rows · Empagliflozin: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapagliflozin
Rows use multiple source trials
Empagliflozin
Rows use multiple source trials
DBP
absolute change · mmHg
-0.25 vs 2.36 Glimepiride mmHg @ 52wka,b,c,d
NCT02564926 · Phase 4 · registry result, not featured evidence
-3.37 vs -1.59 placebo mmHg @ 24wk10 mge,a,b,c,d
NCT04233801 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.94 vs -1.59 placebo mmHg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.74% (n=19) @ 26wk10 mge,f,b,c,g
NCT03199053 · Phase 3
show 1 more dose
-0.71% (n=21) @ 26wk5 mg
NCT03199053 · Phase 3
-0.55% (n=32) @ 52wk10 mge,f,b,c,g
NCT02589626 · Phase 4 · registry result, not featured evidence
show 1 more dose
-0.77% (n=33) @ 52wk25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
Lean Mass
absolute change · kg
-1.1 vs 0.2 Glimepiride kg @ 52wkb,c
NCT02564926 · Phase 4 · registry result, not featured evidence
-1.61 vs -1.08 placebo kg @ 52wk10 mgb,c
NCT04531462 · Phase 4 · registry result, not featured evidence
SBP
absolute change · mmHg
-2.18 vs 4.63 Glimepiride mmHg @ 52wka,b,c,d
NCT02564926 · Phase 4 · registry result, not featured evidence
-5.56 vs -1.95 placebo mmHg @ 24wk10 mge,a,b,c,d
NCT04233801 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.96 vs -1.95 placebo mmHg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
Seated SBP
absolute change · mmHg
-4.04 vs -0.27 placebo mmHg @ 8wk10 mgh,i,j
NCT01392677 · Phase 3 · combination
1 other source trial
-5.98 vs -5.12 placebo mmHg @ 8wk
NCT00984867 · Phase 3
-0.12 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mge,h,i,j
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
2.63 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Dropout rate
18.6%10 mg AMk
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
14.5%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.8%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.8%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
16.2%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.7%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
0%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
14.2%Dapagliflozin
NCT00859898 · Phase 3
13.3%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
16.3%5 mg
NCT00643851 · Phase 3
8.8%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
11.9%10 mg
NCT00528879 · Phase 3 · combination
10.9%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
12.4%2.5 mg
NCT00528879 · Phase 3 · combination
20.7%
NCT00660907 · Phase 3 · combination
6.6%10 mg
NCT00680745 · Phase 3 · combination
9%5 mg
NCT00680745 · Phase 3 · combination
9.1%2.5 mg
NCT00680745 · Phase 3 · combination
7.3%10 mg
NCT01392677 · Phase 3 · combination
10%10MG
NCT00683878 · Phase 3 · combination
11.3%5MG
NCT00683878 · Phase 3 · combination
7.6%
NCT00984867 · Phase 3
9.2%10mg
NCT00673231 · Phase 3
12.3%5mg
NCT00673231 · Phase 3
10.9%2.5mg
NCT00673231 · Phase 3
2.5%10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
6.2%Dapagliflozin
NCT03199053 · Phase 3 · background therapy
1.3%10 mg
NCT01730534 · Phase 3
16.7%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
16.7%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
12.9%
NCT03782259 · Phase 4 · registry result, not featured evidence
16%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
7.4%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
7.7%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
8.3%
NCT03074630 · Phase 4 · registry result, not featured evidence
13.3%
NCT02564926 · Phase 4 · registry result, not featured evidence
23.7%10 mgl
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
23.2%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
8%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
8.7%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
15.9%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
6.2%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
11.2%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
4.4%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
9.4%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
6.1%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
2.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.5%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
18.1%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
10.2%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
7.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5.3%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
7.7%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
8.6%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6.4%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
7.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
8.6%10 mg AMk
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
4.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
—20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.1%Dapagliflozin
NCT00859898 · Phase 3
1.9%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
3%5 mg
NCT00643851 · Phase 3
1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
3%10 mg
NCT00528879 · Phase 3 · combination
1.5%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
2.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.1%
NCT00660907 · Phase 3 · combination
2%10 mg
NCT00680745 · Phase 3 · combination
2.1%5 mg
NCT00680745 · Phase 3 · combination
3.2%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
2.1%10MG
NCT00683878 · Phase 3 · combination
2.1%5MG
NCT00683878 · Phase 3 · combination
3.1%
NCT00984867 · Phase 3
3.1%10mg
NCT00673231 · Phase 3
4.2%5mg
NCT00673231 · Phase 3
2.5%2.5mg
NCT00673231 · Phase 3
—10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
—10 mg
NCT01730534 · Phase 3
—Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
—T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
—Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
—Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
4%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
—10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
—
NCT02433678 · Phase 4 · registry result, not featured evidence
—10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
—
NCT02564926 · Phase 4 · registry result, not featured evidence
11.4%10 mgl
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
11.6%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.9%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
3.2%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.6%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
5.6%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.3%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.1%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
1.7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
2.4%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
0%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.9%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.3%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
—10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
5.9%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
1.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Serious AEs
1.4%10 mg AMk
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
7.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.2%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
2.3%Dapagliflozin
NCT00859898 · Phase 3
1.4%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
4.4%5 mg
NCT00643851 · Phase 3
3.1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
10.4%10 mg
NCT00528879 · Phase 3 · combination
—5 mg
NCT00528879 · Phase 3 · combination
6.6%5.0 mg
NCT00528879 · Phase 3 · combination
10.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.6%
NCT00660907 · Phase 3 · combination
6%10 mg
NCT00680745 · Phase 3 · combination
6.9%5 mg
NCT00680745 · Phase 3 · combination
7.1%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
1.4%10MG
NCT00683878 · Phase 3 · combination
2.8%5MG
NCT00683878 · Phase 3 · combination
4.4%
NCT00984867 · Phase 3
7.1%10mg
NCT00673231 · Phase 3
4.7%5mg
NCT00673231 · Phase 3
7.4%2.5mg
NCT00673231 · Phase 3
5.6%10mg QD
NCT02413398 · Phase 3
0%10 mg
NCT03199053 · Phase 3
4.8%10 mg
NCT03199053 · Phase 3
0%10 mg
NCT03199053 · Phase 3 · combination
1.2%5 mg
NCT03199053 · Phase 3
0%5 mg
NCT03199053 · Phase 3
9.1%5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
37.4%10 mg
NCT01730534 · Phase 3
0%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
0%
NCT02235298 · Phase 4 · registry result, not featured evidence
0%
NCT02796170 · Phase 4 · registry result, not featured evidence
0%10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
0%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
0%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
10%
NCT02564926 · Phase 4 · registry result, not featured evidence
37.4%10 mgl
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
39%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
4.9%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.2%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
0.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
5.4%10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
0%25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
12.3%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
10.5%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
8.9%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
6.3%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
13.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
9.6%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.7%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0.6%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
1.8%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
3.8%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
2.3%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
0.9%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
3.2%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mg AMk
nasopharyngitis 14.3% (placebo 9.3%)
arthralgia 8.6% (placebo 4%)
headache 8.6% (placebo 12%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 42 more results
10 mg PM
headache 13.2% (placebo 12%)
upper respiratory tract infection 11.8% (placebo 5.3%)
back pain 9.2% (placebo 6.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg AM
pharyngitis 9.4% (placebo 8%)
arthralgia 7.8% (placebo 4%)
headache 7.8% (placebo 12%)
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
5 mg PM
headache 16.2% (placebo 12%)
nasopharyngitis 13.2% (placebo 9.3%)
arthralgia 11.8% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg AM
nasopharyngitis 16.9% (placebo 9.3%)
influenza 10.8% (placebo 4%)
arthralgia 9.2% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg PM
nasopharyngitis 16.4% (placebo 9.3%)
abdominal pain 9% (placebo 2.7%)
dizziness 9% (placebo 2.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
back pain 12.5% (placebo 8.7%)
headache 12.5% (placebo 8.7%)
fatigue 8.3% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
20 mg
nausea 12.5% (placebo 4.3%)
pollakiuria 12.5% (placebo 17.4%)
vomiting 12.5% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
urinary tract infection 7.8%
vulvovaginal mycotic infection 5%
diarrhoea 2.7%
NCT00859898 · Phase 3
diarrhoea 7.1%
vulvovaginal mycotic infection 3.3%
urinary tract infection 2.8%
NCT00859898 · Phase 3 · combination
5 mg
dyslipidaemia 5.4%
upper respiratory tract infection 4.9%
urinary tract infection 4.4%
NCT00643851 · Phase 3
diarrhoea 7.7%
nausea 5.7%
upper respiratory tract infection 5.2%
NCT00643851 · Phase 3 · combination
10 mg
back pain 13.3% (placebo 8%)
influenza 12.6% (placebo 10.9%)
diarrhoea 11.9% (placebo 7.3%)
NCT00528879 · Phase 3 · combination
5.0 mg
influenza 14.6% (placebo 10.9%)
headache 9.5% (placebo 5.8%)
arthralgia 7.3% (placebo 5.1%)
NCT00528879 · Phase 3 · combination
2.5 mg
influenza 13.9% (placebo 10.9%)
nasopharyngitis 11.7% (placebo 8.8%)
back pain 8% (placebo 8%)
NCT00528879 · Phase 3 · combination
nasopharyngitis 10.6%
hypertension 7.4%
influenza 7.4%
NCT00660907 · Phase 3 · combination
10 mg
hypoglycemia 7.9% (placebo 4.8%)
nasopharyngitis 3.3% (placebo 2.7%)
hypertension 1.3% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
5 mg
hypoglycemia 6.9% (placebo 4.8%)
nasopharyngitis 5.5% (placebo 2.7%)
hypertension 1.4% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
2.5 mg
hypoglycemia 7.1% (placebo 4.8%)
hypertension 5.2% (placebo 4.1%)
nasopharyngitis 1.9% (placebo 2.7%)
NCT00680745 · Phase 3 · combination
10 mg
urinary tract infection 4.6% (placebo 6.4%)
NCT01392677 · Phase 3 · combination
10MG
dyslipidaemia 9.3% (placebo 4.3%)
nasopharyngitis 7.9% (placebo 3.6%)
diarrhoea 6.4% (placebo 4.3%)
NCT00683878 · Phase 3 · combination
5MG
upper respiratory tract infection 6.4% (placebo 5.8%)
dyslipidaemia 5.7% (placebo 4.3%)
nasopharyngitis 5% (placebo 3.6%)
NCT00683878 · Phase 3 · combination
nasopharyngitis 4% (placebo 6.2%)
NCT00984867 · Phase 3
10mg
hypoglycemia 44.9% (placebo 42.1%)
nasopharyngitis 8.7% (placebo 11.2%)
urinary tract infection 5.6% (placebo 3%)
NCT00673231 · Phase 3
5mg
hypoglycemia 47.6% (placebo 42.1%)
nasopharyngitis 13.7% (placebo 11.2%)
hypertension 6.1% (placebo 8.1%)
NCT00673231 · Phase 3
2.5mg
hypoglycemia 55% (placebo 42.1%)
nasopharyngitis 13.9% (placebo 11.2%)
hypertension 5.4% (placebo 8.1%)
NCT00673231 · Phase 3
10 mg
abdominal pain 4.8% (placebo 2.6%)
abdominal pain upper 4.8% (placebo 0%)
bronchitis 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
dysmenorrhoea 9.5% (placebo 2.6%)
headache 9.5% (placebo 1.3%)
conjunctivitis allergic 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
pharyngotonsillitis 14.3% (placebo 1.3%)
tonsillitis 14.3% (placebo 0%)
abdominal pain 0% (placebo 2.6%)
NCT03199053 · Phase 3 · combination
5 mg
headache 7.4% (placebo 1.3%)
hypertriglyceridaemia 4.9% (placebo 1.3%)
diarrhoea 3.7% (placebo 3.9%)
NCT03199053 · Phase 3
5 mg
headache 9.1% (placebo 1.3%)
nasopharyngitis 3.6% (placebo 2.6%)
anxiety 1.8% (placebo 0%)
NCT03199053 · Phase 3
5 mg
influenza 5.5% (placebo 2.6%)
abdominal pain upper 3.6% (placebo 0%)
headache 3.6% (placebo 1.3%)
NCT03199053 · Phase 3
10 mg
renal impairment 1.4% (placebo 1.7%)
acute kidney injury 1% (placebo 1.3%)
chronic kidney disease 0.9% (placebo 1.2%)
NCT01730534 · Phase 3
genital mycotic infection 13.3%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
genital mycotic infection 26.7%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
transcient syncope 12.5% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
transcient syncope 0% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
nausea and vomiting 24% (placebo 0%)
genital mycosis 0% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence
nausea and vomiting 20% (placebo 0%)
genital mycosis 8% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
dysuria 12% (placebo 0%)
frequency of urination 12% (placebo 0%)
balanitis 2% (placebo 0%)
NCT02235298 · Phase 4 · registry result, not featured evidence
cold like symptoms 4.5%
genital yeast infection 4.5%
abrasion of left cornea 2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
10mg Once Daily
genital fungal infections 20.8%
NCT02682563 · Phase 4 · registry result, not featured evidence
nasopharyngitis 6.7%
toothache 6.7%
hypoglycaemia 5%
NCT02564926 · Phase 4 · registry result, not featured evidence
10 mgl
hypoglycaemia 29.6% (placebo 29.4%)
urinary tract infection 14.5% (placebo 14.7%)
hyperglycaemia 9.3% (placebo 18.1%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 37 more results
25 mg
hypoglycaemia 28.7% (placebo 29.4%)
urinary tract infection 14.4% (placebo 14.7%)
nasopharyngitis 9.4% (placebo 9.3%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10mg
hypoglycaemia 15.6% (placebo 9.8%)
urinary tract infection 9.4% (placebo 6.7%)
nasopharyngitis 8% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 5.5% (placebo 4.9%)
urinary tract infection 4.1% (placebo 6.7%)
hyperglycaemia 2.3% (placebo 12.4%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 12.9% (placebo 9.8%)
urinary tract infection 6.9% (placebo 6.7%)
nasopharyngitis 6% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 8.9% (placebo 9.8%)
hyperglycaemia 7.9% (placebo 12.4%)
nasopharyngitis 5% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7% (placebo 4.9%)
upper respiratory tract infections 4.2% (placebo 5.3%)
urinary tract infection 4.2% (placebo 6.7%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7.2% (placebo 4.9%)
urinary tract infection 7.2% (placebo 6.7%)
diarrhoea 5.8% (placebo 0%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
10 mg
headache 16.2% (placebo 15.5%)
hypoglycaemia 16.2% (placebo 12.1%)
vitamin d deficiency 13.5% (placebo 13.8%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
25 mg
hypoglycaemia 17.2% (placebo 12.1%)
blood ketone body increased 10.3% (placebo 3.4%)
headache 10.3% (placebo 15.5%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
10 mg
constipation 10.8% (placebo 4.7%)
pyrexia 6.2% (placebo 4.7%)
nasopharyngitis 4.6% (placebo 6.3%)
NCT04531462 · Phase 4 · registry result, not featured evidence
10 mg
nasopharyngitis 34.9% (placebo 31.1%)
hypoglycaemia 27.9% (placebo 21.1%)
pollakiuria 10.5% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
25 mg
hypoglycaemia 27.8% (placebo 21.1%)
nasopharyngitis 26.7% (placebo 31.1%)
pollakiuria 10% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
10 mg
viral upper respiratory tract infection 31.3%
fall 3.1%
influenza 0%
NCT02589626 · Phase 4 · registry result, not featured evidence
25mg
viral upper respiratory tract infection 33.3%
influenza 9.1%
fall 6.1%
NCT02589626 · Phase 4 · registry result, not featured evidence
10 mg
hypoglycaemia 20.5% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg
hypoglycaemia 15.1% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg-25 mg
lipase increased 7.5% (placebo 3.9%)
cough 6.3% (placebo 1.3%)
upper respiratory tract infection 2.5% (placebo 5.2%)
NCT02182830 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg qd
dyslipidaemia 8.7%
urinary tract infection 7%
upper respiratory tract infection 2.9%
NCT01719003 · Phase 3 · registry result, not featured evidence
25 mg qd
urinary tract infection 7.8%
dyslipidaemia 6.6%
upper respiratory tract infection 4.2%
NCT01719003 · Phase 3 · registry result, not featured evidence
12.5 mg Bid + 1000 mg Bid
diarrhoea 7.5%
dizziness 5.7%
gastritis 5.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 1000 mg Bid
urinary tract infection 10.6%
diarrhoea 7.1%
dyslipidaemia 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 500 mg Bid
urinary tract infection 10%
dizziness 5.3%
diarrhoea 3.5%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 1000 mg Bid
urinary tract infection 7%
dyslipidaemia 4.7%
upper respiratory tract infection 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 500 mg Bid
dyslipidaemia 8.9%
diarrhoea 5.3%
urinary tract infection 5.3%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10 mg
nasopharyngitis 10% (placebo 4.8%)
anal inflammation 0% (placebo 0%)
bartholinitis 0% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
25 mg
anal inflammation 5.3% (placebo 0%)
bartholinitis 5.3% (placebo 0%)
pollakiuria 5.3% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
25 mg
ketosis 19.4% (placebo 3.3%)
fatigue 9.7% (placebo 0%)
headache 9.7% (placebo 10%)
NCT02632747 · Phase 2 · registry result, not featured evidence
10 mg QD
urinary tract infection 6.8% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
25 mg QD
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
12.5 mg BID
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
5 mg BID
urinary tract infection 3.7% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 24 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gAssessment timepoints differ: 26 weeks versus 52 weeks.
  8. hPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
  9. iTreatment context differs: combination versus pooled.
  10. jAssessment timepoints differ: 8 weeks versus 26 weeks.
  11. kPopulation comparability has not been reviewed for 44 of these studies.
  12. lPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

Fasting Plasma Glucose -4.68 mmol/L @ 24wk10 mg AM
absolute change · mmol/L
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -84.3 mg/dL as posted
show 5 more results
-4.12 mmol/L @ 1wk*10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -74.3 mg/dL as posted
-1.62 mmol/L @ 26wk10 mg
NCT03199053 · Phase 3
-4.27 mmol/L @ 24wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -77 mg/dL as posted
-3.01 mmol/L @ 1wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -54.3 mg/dL as posted
-0.98 mmol/L @ 26wk5 mg
NCT03199053 · Phase 3
Weight -1.9 kg @ 24wk10 mg AM
absolute change · kg
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
-2.06 kg @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.1% (n=14) vs 14.5% (n=11) placebo @ 24wk10 mg AM
responder rate · % of participants
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
26% (n=73) vs 14.5% (n=11) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
26.6% (n=17) vs 14.5% (n=11) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
25.8% (n=63) vs 14.5% (n=11) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
27.2% (n=17) vs 14.5% (n=11) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.4% (n=62) vs 14.5% (n=11) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
25.2% (n=36) vs 13.8% (n=18) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
14.5% (n=18) vs 13.8% (n=18) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
20.7% (n=29) vs 13.8% (n=18) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
HbA1c 7.0 or Less 13% (n=23) vs 5.3% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 3 Participants as posted
show 1 more result
4.3% (n=23) vs 5.3% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
HbA1c Less Than or Equal to 6.5 4.3% (n=23) vs 0% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
show 1 more result
0% (n=23) vs 0% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 0 Participants as posted
HbA1C Decrease at Least 0.5 65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
show 1 more result
65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
TDDI Change Units Per -1.35 vs 1.69 placebo per day @ 12wk10 mg
absolute change · per day
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
show 4 more results
-1.16 vs 5.08 placebo per day @ 24wk10mg
NCT00673231 · Phase 3
-0.83 vs 1.69 placebo per day @ 12wk20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
-0.61 vs 5.08 placebo per day @ 24wk5mg
NCT00673231 · Phase 3
-1.8 vs 5.08 placebo per day @ 24wk2.5mg
NCT00673231 · Phase 3
HbA1c Less Than 7 46.6% (n=202) vs 35.5% (n=203) Metformin XR @ 24wk
absolute value · percentage points
NCT00859898 · Phase 3 · combination
show 1 more result
31.7% (n=216) vs 35.5% (n=203) Metformin XR @ 24wk
NCT00859898 · Phase 3
Weight Loss 5% 33.3% (n=400) vs 2.5% (n=401) Glipizide Plus Metformin @ 52wk
responder rate · % of participants
NCT00660907 · Phase 3 · combination
OGTT 2 h Change mg/dL -34.9 vs -6 placebo mg/dL @ 24wk10 mg
absolute change · mg/dL
NCT00680745 · Phase 3 · combination
show 2 more results
-32 vs -6 placebo mg/dL @ 24wk5 mg
NCT00680745 · Phase 3 · combination
-37.5 vs -6 placebo mg/dL @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
PPG 2h Change mg/dL -3.75 vs -0.78 placebo mmol/L @ 24wk10MG
absolute change · mmol/L
NCT00683878 · Phase 3 · combination · converted to mmol/L from -67.5 mg/dL as posted
show 2 more results
-3.61 vs -0.78 placebo mmol/L @ 24wk*5MG
NCT00683878 · Phase 3 · combination · converted to mmol/L from -65.1 mg/dL as posted
-1.2 vs -0.38 placebo mmol/L @ 24wk*
NCT00984867 · Phase 3 · converted to mmol/L from -21.65 mg/dL as posted
Waist Circumference Change -0.17 vs 1.38 placebo cm @ 24wk10MG
absolute change · cm
NCT00683878 · Phase 3 · combination
show 2 more results
0.52 vs 1.38 placebo cm @ 24wk5MG
NCT00683878 · Phase 3 · combination
-2.37 vs -0.16 Glimepiride cm @ 52wk
NCT02564926 · Phase 4 · registry result, not featured evidence

+ 32 further endpoints in the CSV export.

Empagliflozin

MACE 3-point Composite 10.4% (n=2345) vs 12.1% (n=2333) placebo10 mg
event count · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
10.5% (n=2342) vs 12.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10.5% (n=4687) vs 12.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
MACE 4-point Composite 12.8% (n=2345) vs 14.3% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
12.8% (n=2342) vs 14.3% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
12.8% (n=4687) vs 14.3% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Silent MI 1.6% (n=1174) vs 1.2% (n=1211) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
1.6% (n=1204) vs 1.2% (n=1211) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
1.6% (n=2378) vs 1.2% (n=1211) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
HF Hospitalization 2.6% (n=2345) vs 4.1% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
2.8% (n=2342) vs 4.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7% (n=4687) vs 4.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Albuminuria 51.5% (n=1403) vs 51.2% (n=1374) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
51.5% (n=1376) vs 51.2% (n=1374) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
51.5% (n=2779) vs 51.2% (n=1374) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Macroalbuminuria 10.9% (n=2037) vs 16.2% (n=2033) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
11.5% (n=2054) vs 16.2% (n=2033) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
11.2% (n=4091) vs 16.2% (n=2033) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Composite Microvascular Outcome 13.9% (n=2057) vs 20.5% (n=2068) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
14.1% (n=2075) vs 20.5% (n=2068) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
14% (n=4132) vs 20.5% (n=2068) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Daily Plasma Glucose Change mg/dL -0.54 vs -0.11 placebo mmol/L @ 24wk10mg
absolute change · mmol/L
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -9.64 mg/dL as posted
show 5 more results
-0.56 vs -0.11 placebo mmol/L @ 24wk*10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.01 mg/dL as posted
-0.8 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.36 mg/dL as posted
-1.97 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -35.47 mg/dL as posted
-0.72 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -13.06 mg/dL as posted
-1.63 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -29.34 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk10 mg, 25 mg
responder rate · % of participants
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Time to Treatment Failure 5.5 vs 2.16 placebo months10 mg, 25 mg
time to event · months
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 · converted to months from 167.333 days as posted
Fasting Plasma Glucose Change mg/dL -19.48 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
absolute change · mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 3 more results
-18.45 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-25.61 vs -5.56 placebo mg @ 24wk10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
-29.69 vs -5.56 placebo mg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
Seated DBP 0.78 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg
absolute change · mmHg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 3 more results
-3.2 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-4.14 vs -2.3 placebo mmHg @ 12wk10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
-5.55 vs -1.3 placebo mmHg @ 24wk10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03036150 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of kidney failure and death, and dapagliflozin significantly reduced this composite compared with placebo.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. (Up to 38.2 months): Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001 (met)

Result source: NCT03036150

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03594110 · Phase 3 · completed

Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).

Next expected readout: December 2026 · NCT05786443 (registry estimate)

Reported efficacy

Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)

Result source: NCT03594110

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapagliflozinEmpagliflozin
Kidney composite outcome6.6% vs 11.3%−4.7 vs placebon 2152NCT030361506.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110
UACR, % change-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840
eGFR slope—Not posted · NCT05998837—Not posted · NCT05373680
Haemoglobin, change—Not posted · NCT05998837—Not posted · NCT05373680

Kidney composite outcome

Dapagliflozin
6.6% vs 11.3%−4.7 vs placebon 2152NCT03036150
Empagliflozin
6.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110

UACR, % change

Dapagliflozin
-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
Empagliflozin
-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840

eGFR slope

Dapagliflozin
—Not posted · NCT05998837
Empagliflozin
—Not posted · NCT05373680

Haemoglobin, change

Dapagliflozin
—Not posted · NCT05998837
Empagliflozin
—Not posted · NCT05373680
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Dapagliflozin: 8 of 8 rows · Empagliflozin: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapagliflozin
Rows use multiple source trials
Empagliflozin
Rows use multiple source trials
Overall Survival
time to event · count
4.7% vs 6.8% placeboa,b,c
NCT03036150 · Phase 3
0.1% vs 0.1% placebo10 mga,b,c
NCT03594110 · Phase 3
Time to Cardio-renal Composite Endpoint
event count · % of participants
9.2% (n=2152) vs 14.5% (n=2152) placebo*a,b,c
NCT03036150 · Phase 3 · converted to % from 197 Participants as posted
6.85% (n=3304) vs 8.96% (n=3305) placebo10 mgd,a,b,c
NCT03594110 · Phase 3
show 1 more dose
8.36% (n=3304) vs 9.99% (n=3305) placebo10 mg
NCT03594110 · Phase 3
UACR
absolute change · mg
0.48 vs 0.72 placebo mg @ 12wk1.5 mgd,a,e
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
show 3 more doses
0.48 vs 0.72 placebo mg @ 12wk1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.52 vs 0.72 placebo mg @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.52 vs 0.72 placebo mg @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
-0.496 vs -0.027 placebo mg @ 14wk10 mgd,a,e
NCT05182840 · Phase 2 · registry result, not featured evidence
show 5 more doses
-0.455 vs -0.027 placebo mg @ 14wk20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
-0.614 vs -0.112 Empagliflozin mg @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.516 vs -0.112 Empagliflozin mg @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.21 vs -0.112 Empagliflozin mg @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.254 vs -0.027 placebo mg @ 14wk3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
UACR 30
responder rate · % of participants
45% (n=144) vs 31.3% (n=148) placebo @ 24wk10 mgd,f,g,h
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more dose
57% (n=152) vs 31.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
50.8% (n=61) vs 14.5% (n=69) placebo @ 14wk*10 mgd,f,g,h
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 31 Participants as posted
show 23 more doses
45.9% (n=61) vs 13% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
50.8% (n=61) vs 20.3% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 31 Participants as posted
50% (n=56) vs 13.6% (n=66) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
50.8% (n=59) vs 14.5% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted
42.4% (n=59) vs 13% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
54.2% (n=59) vs 20.3% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
50% (n=50) vs 13.6% (n=66) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
70% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 42 Participants as posted
56.7% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
60% (n=60) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted
66.7% (n=51) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
58.1% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted
51.6% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
66.1% (n=62) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
57.1% (n=56) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted
33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted
36.5% (n=63) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
33.3% (n=63) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted
29.2% (n=65) vs 14.5% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
29.2% (n=65) vs 13% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
33.8% (n=65) vs 20.3% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
31.1% (n=61) vs 13.6% (n=66) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
Dropout rate
—10 mgi
NCT03036150 · Phase 3
show 10 more results
0.5%Dapagliflozin
NCT03036150 · Phase 3
5.5%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
3.2%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
17.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
25%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
20.7%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
9.9%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
22.9%10 mgi
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—10 mgi
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
—10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
—10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
2.9%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3.9%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
7.2%10 mgi
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Serious AEs
29.5%10 mgi
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
8.3%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
7.9%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
12.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.6%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
1.9%10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
33%10 mgi
NCT03594110 · Phase 3
show 9 more results
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
8.3%20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
9.6%10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
6.8%10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
5.3%10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
4.3%3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mgi
nasopharyngitis 4.3% (placebo 3.8%)
urinary tract infection 3.6% (placebo 3.7%)
hypoglycaemia 3.4% (placebo 3.3%)
NCT03036150 · Phase 3
show 9 more results
10 mg
nasopharyngitis 6.9% (placebo 4.1%)
influenza 5.5% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence
10 mg + 2.5 mg
nasopharyngitis 6.6% (placebo 4.1%)
influenza 1.3% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
10 mg
hyperkalaemia 9.1% (placebo 0%)
urinary tract infection 9.1% (placebo 0%)
fall 6.1% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
1.5 mg
brain natriuretic peptide increased 5% (placebo 0.6%)
headache 4.5% (placebo 1.1%)
metabolic acidosis 3.9% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.25 mg
headache 6.6% (placebo 1.1%)
hypertension 5.5% (placebo 0.6%)
metabolic acidosis 5.5% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
10 mg
any adverse event 32.1% (placebo 25%)
NCT03190694 · Phase 2 · registry result, not featured evidence
10 mgi
gout 6.9% (placebo 7.9%)
NCT03594110 · Phase 3
show 8 more results
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
10 mg
glomerular filtration rate decreased 9.9% (placebo 4.1%)
hyperkalaemia 9.9% (placebo 5.5%)
cortisol decreased 5.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence
20 mg
hyperkalaemia 23.6% (placebo 5.5%)
glomerular filtration rate decreased 8.3% (placebo 4.1%)
upper respiratory tract infection 4.2% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence
10 mg + 10 mg
hyperkalaemia 15.1% (placebo 5.5%)
glomerular filtration rate decreased 11% (placebo 4.1%)
hypotension 5.5% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 20 mg
glomerular filtration rate decreased 9.5% (placebo 4.1%)
hyperkalaemia 9.5% (placebo 5.5%)
upper respiratory tract infection 5.4% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 3 mg
hyperkalaemia 6.6% (placebo 5.5%)
glomerular filtration rate decreased 5.3% (placebo 4.1%)
cortisol decreased 2.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
3 mg
hyperkalaemia 11.4% (placebo 5.5%)
cortisol decreased 4.3% (placebo 0%)
upper respiratory tract infection 2.9% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 12 weeks versus 14 weeks.
  6. fTrial phases differ: Phase 2/3 versus Phase 2.
  7. gPopulation context differs: registered conditions differ.
  8. hAssessment timepoints differ: 24 weeks versus 14 weeks.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

Time to CV Death or HF Hospitalization 4.6% (n=2152) vs 6.4% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 100 Participants as posted
HbA1c -0.43% (n=140) vs -0.27% (n=145) placebo @ 24wk10 mg
absolute change · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.85% (n=151) vs -0.27% (n=145) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Weight -1.48% (n=144) vs -0.61% (n=148) placebo @ 24wk10 mg
percent change · % of baseline
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.65% (n=152) vs -0.61% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose Change mg/dL -13.1 vs -11.2 placebo mg @ 24wk10 mg
absolute change · mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-17.2 vs -11.2 placebo mg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
HbA1c Less Than 7 15% (n=144) vs 10.3% (n=148) placebo @ 24wk10 mg
absolute value · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
35.1% (n=152) vs 10.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Seated SBP -6.9 vs -4.1 placebo mmHg @ 24wk10 mg
absolute change · mmHg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-8.8 vs -4.1 placebo mmHg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
eGFR -3.498 vs 6.88 placebo mL @ 12wk10 mg
absolute change · mL
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
-5.307 vs 6.88 placebo mL @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.16 vs 6.88 placebo mL @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.432 vs 6.88 placebo mL @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
SBP -11 vs -3.4 placebo mmHg @ 12wk1.5 mg
absolute change · mmHg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-7.1 vs -3.4 placebo mmHg @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
DBP -6.8 vs -1.4 placebo mmHg @ 12wk1.5 mg
absolute change · mmHg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-4.3 vs -1.4 placebo mmHg @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
eGFR -3.9 vs -3.1 placebo m @ 1wk1.5 mg
absolute change · m
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
-3 vs -1.9 placebo m @ 12wk1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
-2 vs 0.1 placebo m @ 14wk1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.9 vs 1.2 placebo m @ 12wk1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
-2 vs -3.1 placebo m @ 1wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
-3.1 vs -1.9 placebo m @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.2 vs 0.1 placebo m @ 14wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
-1.1 vs 1.2 placebo m @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
Proteinuria -15.04% (n=53) vs -15.8% (n=52) placebo @ 6wk10 mg
percent change · % of baseline
NCT03190694 · Phase 2 · registry result, not featured evidence

Empagliflozin

Time to Cardiovascular Composite Endpoint 2.04% (n=3304) vs 2.39% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to CV Death 0.91% (n=3304) vs 1.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to CV Death or ESKD 2.55% (n=3304) vs 3.45% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to Death or ESKD 5.13% (n=3304) vs 6.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to ESKD 2.72% (n=3304) vs 3.49% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
UACR 0.483 vs 0.708 Empagliflozin ratio @ 25.7wk
ratio to baseline · ratio
NCT05254002 · Phase 2 · registry result, not featured evidence
show 2 more results
0.483 vs 0.683 Finerenone ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.818 vs 0.853 Finerenone ratio @ 30wk
NCT05254002 · Phase 2 · registry result, not featured evidence
eGFR 30% Decline 6.3% (n=268) vs 3.8% (n=264) Finerenone @ 4.3wk
event count · % of participants
NCT05254002 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
UACR 15 57.4% (n=61) vs 31.9% (n=69) placebo @ 14wk10 mg
responder rate · % of participants
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 35 Participants as posted
show 23 more results
52.5% (n=61) vs 29% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
67.2% (n=61) vs 36.2% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 41 Participants as posted
57.1% (n=56) vs 30.3% (n=66) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
66.1% (n=59) vs 31.9% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 39 Participants as posted
54.2% (n=59) vs 29% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
69.5% (n=59) vs 36.2% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 41 Participants as posted
64% (n=50) vs 30.3% (n=66) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
55.6% (n=63) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 35 Participants as posted
78.3% (n=60) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
67.7% (n=62) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 42 Participants as posted
55.6% (n=63) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 35 Participants as posted
65% (n=60) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
61.3% (n=62) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 38 Participants as posted
61.9% (n=63) vs 43.8% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
76.7% (n=60) vs 43.8% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 46 Participants as posted
71% (n=62) vs 43.8% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 44 Participants as posted
55.6% (n=63) vs 39.3% (n=61) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 35 Participants as posted
76.5% (n=51) vs 39.3% (n=61) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
67.9% (n=56) vs 39.3% (n=61) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 38 Participants as posted
50.8% (n=65) vs 31.9% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
49.2% (n=65) vs 29% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
43.1% (n=65) vs 36.2% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
52.5% (n=61) vs 30.3% (n=66) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted

Heart Failure

Shared mechanism: SGLT2 · full Heart Failure pipeline

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Heart Failuresmall molecule
Reliable signal

NCT03036124 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of death and hospitalization, and dapagliflozin significantly reduced this composite compared with placebo.

Next expected readout: December 2026 · NCT06578520 (registry estimate)

Reported efficacy

Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) (29 months): Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo) (met)

Result source: NCT04564742

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Heart Failuresmall molecule
Reliable signal

NCT03057951 · Phase 3 · completed

This trial randomized patients to empagliflozin or matching placebo under double-blind conditions in a very large group, and measured a hard clinical outcome: cardiovascular death or hospitalization for heart failure. Empagliflozin significantly lowered this combined event rate compared with placebo (hazard ratio 0.79, 95% CI 0.69-0.90, p=0.0003).

Next expected readout: November 2026 · NCT05057806 (registry estimate)

Reported efficacy

Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) (From randomization until completion of the planned treatment phase, up to 1403 days.): Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction. (met)

Result source: NCT03057951

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapagliflozinEmpagliflozin
CV death or HF hospitalisation16.1% vs 20.9%−4.8 vs placebo10 mg · n 2373NCT03036124
1 other result
  • 9% vs 11.2% wk 8 · n 1218 · Phase 4 · secondary NCT04363697
—Not posted · NCT05364190
HF hospitalisation—Not posted · NCT056766845.3% vs 4.5%+0.8 vs placebo10 mg · n 265NCT04157751
CV death7.4% vs 8.3%−0.9 vs placebo10 mg · n 3131NCT03619213
1 other result
  • 0% vs 0% wk 26 · n 46 · Phase 4 · secondary NCT04249778
—Not posted · NCT05364190
KCCQ clinical summary, change68.6 vs 62.8+5.8 vs placebowk 12 · n 162NCT030302354.5 vs 3.2+1.3 vs placebo10 mg · wk 52 · n 2333NCT03057951
1 other result
  • -1.3 vs -3.4 10 mg · wk 52 · n 1401 · Phase 3 · secondary NCT03057977

CV death or HF hospitalisation

Dapagliflozin
16.1% vs 20.9%−4.8 vs placebo10 mg · n 2373NCT03036124
1 other result
  • 9% vs 11.2% wk 8 · n 1218 · Phase 4 · secondary NCT04363697
Empagliflozin
—Not posted · NCT05364190

HF hospitalisation

Dapagliflozin
—Not posted · NCT05676684
Empagliflozin
5.3% vs 4.5%+0.8 vs placebo10 mg · n 265NCT04157751

CV death

Dapagliflozin
7.4% vs 8.3%−0.9 vs placebo10 mg · n 3131NCT03619213
1 other result
  • 0% vs 0% wk 26 · n 46 · Phase 4 · secondary NCT04249778
Empagliflozin
—Not posted · NCT05364190

KCCQ clinical summary, change

Dapagliflozin
68.6 vs 62.8+5.8 vs placebowk 12 · n 162NCT03030235
Empagliflozin
4.5 vs 3.2+1.3 vs placebo10 mg · wk 52 · n 2333NCT03057951
1 other result
  • -1.3 vs -3.4 10 mg · wk 52 · n 1401 · Phase 3 · secondary NCT03057977
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Dapagliflozin: 8 of 8 rows · Empagliflozin: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapagliflozin
Rows use multiple source trials
Empagliflozin
Rows use multiple source trials
6MWD - Change
absolute change · m
1185.76 vs 1548.23 placebo m @ 12wka,b,c
NCT04249778 · Phase 4 · registry result, not featured evidence
2 other source trials
262 vs 242 placebo m @ 12wk
NCT03030235 · Phase 4 · registry result, not featured evidence
303.7 vs 301.3 placebo m @ 12wk
NCT02653482 · Phase 4 · registry result, not featured evidence
10 vs 5 placebo m @ 12wk10 mga,b,c
NCT03448406 · Phase 3 · registry result, not featured evidence
1 other source trial
13.5 vs 18 placebo m @ 12wk10 mg daily
NCT03448419 · Phase 3 · registry result, not featured evidence
CV Death or HF Hospitalization or Urgent Visit Composite
event count · % of participants
16.3% (n=2373) vs 21.2% (n=2371) placebo*10 mgb,c,d
NCT03036124 · Phase 3 · converted to % from 386 Participants as posted
4 other source trials
16.4% (n=3131) vs 19.5% (n=3132) placebo*10 mg
NCT03619213 · Phase 3 · converted to % from 512 Participants as posted
17.3% (n=2200) vs 20.3% (n=2172) placebo*10 mg
NCT03619213 · Phase 3 · converted to % from 381 Participants as posted
10.9% (n=1218) vs 12.7% (n=1183) placebo @ 8wk*
NCT04363697 · Phase 4 · registry result, not featured evidence · converted to % from 133 Participants as posted
10.4% (n=1218) vs 12.3% (n=1183) placebo @ 8wk*
NCT04363697 · Phase 4 · registry result, not featured evidence · converted to % from 127 Participants as posted
55.01% (n=265) vs 78.81% (n=265) placebo @ 18.14wk10 mgb,c,d
NCT04157751 · Phase 3 · registry result, not featured evidence
KCCQ-TSS
absolute change · score
6.1 vs 3.3 placebo score @ 35wk10 mgb,c,e
NCT03036124 · Phase 3
1 other source trial
8.3 vs 5.2 placebo score @ 35wk10 mg
NCT03619213 · Phase 3
36.19 vs 31.73 placebo score @ 12.86wk10 mgb,c,e
NCT04157751 · Phase 3 · registry result, not featured evidence
NTproBNP 20% Reduction
event count · % of participants
32% (n=150) vs 29.3% (n=150) placebo @ 12wk*f,c
NCT03030235 · Phase 4 · registry result, not featured evidence · converted to % from 48 Participants as posted
1 other source trial
42.3% (n=130) vs 28.7% (n=129) placebo @ 12wk*
NCT02653482 · Phase 4 · registry result, not featured evidence · converted to % from 55 Participants as posted
33.3% (n=33) vs 6.3% (n=32) placebo @ 12wk*f,c
NCT03030222 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
Dropout rate
0.2%10 mgg
NCT03036124 · Phase 3
show 15 more results
0.3%10 mg
NCT03619213 · Phase 3
0.2%10 mg
NCT04564742 · Phase 3
3.4%
NCT04363697 · Phase 4 · registry result, not featured evidence
70%
NCT04249778 · Phase 4 · registry result, not featured evidence
9.9%
NCT03030235 · Phase 4 · registry result, not featured evidence
0.8%
NCT02653482 · Phase 4 · registry result, not featured evidence
—Dapagliflozin + Structured Usual C
NCT04298229 · Phase 3 · registry result, not featured evidence · combination
1.7%Dapagliflozin Plus Structured Usua
NCT04298229 · Phase 3 · registry result, not featured evidence · combination
2%10 mg
NCT03877224 · Phase 3 · registry result, not featured evidence
3.2%10mg
NCT03877237 · Phase 3 · registry result, not featured evidence
17.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
25%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0%
NCT04730947 · Phase 2 · registry result, not featured evidence
31.6%10 mgg
NCT03057951 · Phase 3
show 12 more results
25.9%10 mg
NCT03057977 · Phase 3
0%
NCT03030222 · Phase 4 · registry result, not featured evidence
—
NCT03226457 · Phase 4 · registry result, not featured evidence
21.8%10 mg
NCT04509674 · Phase 3 · registry result, not featured evidence
8.4%
NCT03087773 · Phase 3 · registry result, not featured evidence
21.5%10 mg
NCT04157751 · Phase 3 · registry result, not featured evidence
—10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
5.6%10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
8.3%10 mg
NCT03448406 · Phase 3 · registry result, not featured evidence
10.3%10 mg daily
NCT03448419 · Phase 3 · registry result, not featured evidence
2.4%
NCT03200860 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—10 mgg
NCT03036124 · Phase 3
show 15 more results
—10 mg
NCT03619213 · Phase 3
—10 mg
NCT04564742 · Phase 3
—
NCT04363697 · Phase 4 · registry result, not featured evidence
—
NCT04249778 · Phase 4 · registry result, not featured evidence
—
NCT03030235 · Phase 4 · registry result, not featured evidence
—
NCT02653482 · Phase 4 · registry result, not featured evidence
—Dapagliflozin + Structured Usual C
NCT04298229 · Phase 3 · registry result, not featured evidence · combination
—Dapagliflozin Plus Structured Usua
NCT04298229 · Phase 3 · registry result, not featured evidence · combination
—10 mg
NCT03877224 · Phase 3 · registry result, not featured evidence
0.6%10mg
NCT03877237 · Phase 3 · registry result, not featured evidence
2.9%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
—
NCT04730947 · Phase 2 · registry result, not featured evidence
19.2%10 mgg
NCT03057951 · Phase 3
show 12 more results
18.3%10 mg
NCT03057977 · Phase 3
—
NCT03030222 · Phase 4 · registry result, not featured evidence
—
NCT03226457 · Phase 4 · registry result, not featured evidence
16.6%10 mg
NCT04509674 · Phase 3 · registry result, not featured evidence
—
NCT03087773 · Phase 3 · registry result, not featured evidence
8.7%10 mg
NCT04157751 · Phase 3 · registry result, not featured evidence
—10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
5.6%10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
5.7%10 mg
NCT03448406 · Phase 3 · registry result, not featured evidence
5.8%10 mg daily
NCT03448419 · Phase 3 · registry result, not featured evidence
—
NCT03200860 · Phase 2 · registry result, not featured evidence
Serious AEs
37.8%10 mgg
NCT03036124 · Phase 3
show 15 more results
46.5%10 mg
NCT03619213 · Phase 3
22.2%10 mg
NCT04564742 · Phase 3
2%
NCT04363697 · Phase 4 · registry result, not featured evidence
6%
NCT04249778 · Phase 4 · registry result, not featured evidence
19.1%
NCT03030235 · Phase 4 · registry result, not featured evidence
24.4%
NCT02653482 · Phase 4 · registry result, not featured evidence
5%Dapagliflozin + Structured Usual C
NCT04298229 · Phase 3 · registry result, not featured evidence · combination
—Dapagliflozin Plus Structured Usua
NCT04298229 · Phase 3 · registry result, not featured evidence · combination
10.3%10 mg
NCT03877224 · Phase 3 · registry result, not featured evidence
12.2%10mg
NCT03877237 · Phase 3 · registry result, not featured evidence
12.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
19%
NCT04730947 · Phase 2 · registry result, not featured evidence
47.9%10 mgg
NCT03057951 · Phase 3
show 12 more results
41.4%10 mg
NCT03057977 · Phase 3
24.2%
NCT03030222 · Phase 4 · registry result, not featured evidence
8.7%
NCT03226457 · Phase 4 · registry result, not featured evidence
23.7%10 mg
NCT04509674 · Phase 3 · registry result, not featured evidence
13.1%
NCT03087773 · Phase 3 · registry result, not featured evidence
32.3%10 mg
NCT04157751 · Phase 3 · registry result, not featured evidence
2.9%10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
—10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
—10 mg
NCT03332212 · Phase 3 · registry result, not featured evidence
12.7%10 mg
NCT03448406 · Phase 3 · registry result, not featured evidence
13.5%10 mg daily
NCT03448419 · Phase 3 · registry result, not featured evidence
20%
NCT03200860 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mgg
hypotension 3.7% (placebo 3.1%)
cardiac failure 3.2% (placebo 5.5%)
nasopharyngitis 2.7% (placebo 3.2%)
NCT03036124 · Phase 3
show 11 more results
10 mg
cardiac failure 5.7% (placebo 6.8%)
urinary tract infection 3.6% (placebo 3.6%)
atrial fibrillation 2.8% (placebo 2%)
NCT03619213 · Phase 3
urinary tract infection 0.5% (placebo 0.2%)
hypotension 0.4% (placebo 0.3%)
renal impairment 0.4% (placebo 0.2%)
NCT04363697 · Phase 4 · registry result, not featured evidence
elective mitral valve replacement 2% (placebo 0%)
gout arthritis 2% (placebo 0%)
peeling dry skin 2% (placebo 0%)
NCT04249778 · Phase 4 · registry result, not featured evidence
volume depletion 6.2% (placebo 4.3%)
urgent heart failure visit 4.9% (placebo 4.9%)
back pain 0.6% (placebo 0%)
NCT03030235 · Phase 4 · registry result, not featured evidence
volume depletion 7.6% (placebo 5.3%)
urgent heart failure visit 2.3% (placebo 5.3%)
hypotension 1.5% (placebo 0.8%)
NCT02653482 · Phase 4 · registry result, not featured evidence
hypoglycemia 5.9%
hf exacerbation 5%
NCT04298229 · Phase 3 · registry result, not featured evidence · combination
10 mg
hyperkalaemia 9.1% (placebo 0%)
urinary tract infection 9.1% (placebo 0%)
fall 6.1% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
dizziness or dehydration 38.1% (placebo 11.8%)
worsening dyspenea 28.6% (placebo 41.2%)
genitourinary infections 14.3% (placebo 5.9%)
NCT04730947 · Phase 2 · registry result, not featured evidence
10 mgg
hypertension 7.1% (placebo 8.3%)
hypotension 7.1% (placebo 5.9%)
urinary tract infection 6.9% (placebo 5.4%)
NCT03057951 · Phase 3
show 7 more results
10 mg
hypotension 6.4% (placebo 5.9%)
hyperkalaemia 5.3% (placebo 5.9%)
nasopharyngitis 4.8% (placebo 5%)
NCT03057977 · Phase 3
exacerbation of heart failure 9.1% (placebo 9.4%)
hypokalemia 9.1% (placebo 0%)
volume depletion 9.1% (placebo 3.1%)
NCT03030222 · Phase 4 · registry result, not featured evidence
gout 4.3% (placebo 8.7%)
NCT03226457 · Phase 4 · registry result, not featured evidence
urinary tract infection 4.6% (placebo 2.9%)
genital fungal infection 3% (placebo 0.8%)
NCT03087773 · Phase 3 · registry result, not featured evidence
10 mg
hypotension 7.7% (placebo 7.2%)
NCT04157751 · Phase 3 · registry result, not featured evidence
10 mg
urinary tract infection 8.6% (placebo 2.8%)
osteoarthritis 5.7% (placebo 0%)
pruritus 5.7% (placebo 0%)
NCT03332212 · Phase 3 · registry result, not featured evidence
renal/urinary 37.5% (placebo 33.3%)
musculoskeletal 32.5% (placebo 33.3%)
cardiovascular 22.5% (placebo 43.6%)
NCT03200860 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eAssessment timepoints differ: 35 weeks versus 12.86 weeks.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

CV Death or HF Hospitalization Composite 16.1% (n=2373) vs 20.9% (n=2371) placebo10 mg
responder rate · % of participants
NCT03036124 · Phase 3 · converted to % from 382 Participants as posted
show 1 more result
9% (n=1218) vs 11.2% (n=1183) placebo @ 8wk*
NCT04363697 · Phase 4 · registry result, not featured evidence · converted to % from 110 Participants as posted
CV Death or HF Hospitalization or Urgent Visit Total 815 vs 1057 placebo count10 mg
event count · count
NCT03619213 · Phase 3
show 1 more result
605 vs 782 placebo count10 mg
NCT03619213 · Phase 3
CV Death 7.4% (n=3131) vs 8.3% (n=3132) placebo10 mg
responder rate · % of participants
NCT03619213 · Phase 3 · converted to % from 231 Participants as posted
show 1 more result
0% (n=46) vs 0% (n=53) placebo @ 26wk*
NCT04249778 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
HF Hospitalization or Urgent Visit 8.8% (n=1218) vs 9.8% (n=1183) placebo @ 8wk
event count · % of participants
NCT04363697 · Phase 4 · registry result, not featured evidence · converted to % from 107 Participants as posted
Win 172,221 vs 157,615 placebo count @ 8wk
ratio to baseline · count
NCT04363697 · Phase 4 · registry result, not featured evidence
All-cause Mortality or All-cause Hospitalization Composite 0% (n=46) vs 5.7% (n=53) placebo @ 26wk
event count · % of participants
NCT04249778 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
KCCQ-CSS 62.4 vs 66.95 placebo score @ 12wk
absolute value · score
NCT04249778 · Phase 4 · registry result, not featured evidence
show 1 more result
83.36 vs 80.38 placebo score @ 26wk
NCT04249778 · Phase 4 · registry result, not featured evidence
CHQ-SAS 5.25 vs 5.34 placebo score @ 12wk
absolute change · score
NCT04249778 · Phase 4 · registry result, not featured evidence
show 1 more result
5.27 vs 5.27 placebo score @ 26wk
NCT04249778 · Phase 4 · registry result, not featured evidence
NT-proBNP Change 589.25 vs 1083 placebo mL @ 12wk
absolute change · mL
NCT04249778 · Phase 4 · registry result, not featured evidence
show 1 more result
674.5 vs 730 placebo mL @ 26wk
NCT04249778 · Phase 4 · registry result, not featured evidence
HbA1c 8.62% (n=21) vs 8.47% (n=17) placebo @ 12wk
absolute change · percentage points
NCT04249778 · Phase 4 · registry result, not featured evidence
show 4 more results
9.47% (n=21) vs 7.84% (n=17) placebo @ 26wk
NCT04249778 · Phase 4 · registry result, not featured evidence
6.5% (n=162) vs 6.6% (n=162) placebo @ 12wk
NCT03030235 · Phase 4 · registry result, not featured evidence
6.9% (n=130) vs 7.1% (n=129) placebo @ 6wk
NCT02653482 · Phase 4 · registry result, not featured evidence
6.9% (n=130) vs 7.1% (n=129) placebo @ 12wk
NCT02653482 · Phase 4 · registry result, not featured evidence
Non-fatal MI 0% (n=46) vs 0% (n=53) placebo @ 26wk
event count · % of participants
NCT04249778 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
KCCQ-OSS 68.9 vs 64.5 placebo score @ 12wk
absolute change · score
NCT03030235 · Phase 4 · registry result, not featured evidence
show 2 more results
71.1 vs 70.1 placebo score @ 6wk
NCT02653482 · Phase 4 · registry result, not featured evidence
72.6 vs 68.9 placebo score @ 12wk
NCT02653482 · Phase 4 · registry result, not featured evidence

+ 20 further endpoints in the CSV export.

Empagliflozin

eGFR Slope Annualized -1.253 vs -2.616 placebo per year10 mg
event rate · per year
NCT03057951 · Phase 3
Progression to Diabetes 6.12% (n=1001) vs 7.39% (n=979) placebo10 mg
event count · % of participants
NCT03057951 · Phase 3
eGFR Chronic Slope -0.546 vs -2.278 placebo m10 mg
absolute value · m
NCT03057977 · Phase 3
Time to Composite Renal Endpoint 1.56% (n=1863) vs 3.07% (n=1867) placebo10 mg
event count · % of participants
NCT03057977 · Phase 3
Time to CV Death 7.55% (n=1863) vs 8.13% (n=1867) placebo10 mg
event count · % of participants
NCT03057977 · Phase 3
Overall Survival 0.5% vs 0.6% placebo10 mg
time to event · count
NCT03057977 · Phase 3
Type 2 Diabetes Incidence 9.31% (n=632) vs 10.62% (n=636) placebo10 mg
event rate · % of participants
NCT03057977 · Phase 3
All-cause Hospitalization 1364 vs 1570 placebo Hospitalizations for any cause10 mg
absolute value · Hospitalizations for any cause
NCT03057977 · Phase 3
Pulmonary Artery Diastolic Pressure 20.7 vs 22.2 placebo mm @ 12wk
absolute change · mm
NCT03030222 · Phase 4 · registry result, not featured evidence
show 13 more results
21.2 vs 21.4 placebo mm @ 0wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21.2 vs 21.5 placebo mm @ 1wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21.1 vs 21.7 placebo mm @ 2wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21.1 vs 21.8 placebo mm @ 3wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21 vs 21.9 placebo mm @ 4wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21 vs 22 placebo mm @ 5wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21 vs 22.1 placebo mm @ 6wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21 vs 22.1 placebo mm @ 7wk
NCT03030222 · Phase 4 · registry result, not featured evidence
21 vs 22.2 placebo mm @ 8wk
NCT03030222 · Phase 4 · registry result, not featured evidence
20.8 vs 22.2 placebo mm @ 9wk
NCT03030222 · Phase 4 · registry result, not featured evidence
20.7 vs 22.2 placebo mm @ 10wk
NCT03030222 · Phase 4 · registry result, not featured evidence
20.5 vs 22.2 placebo mm @ 11wk
NCT03030222 · Phase 4 · registry result, not featured evidence
20.4 vs 22.1 placebo mm @ 12wk
NCT03030222 · Phase 4 · registry result, not featured evidence
Pulmonary Artery Systolic Pressure 20.4 vs 22.1 placebo mm @ 12wk
absolute change · mm
NCT03030222 · Phase 4 · registry result, not featured evidence
show 13 more results
44.1 vs 43.9 placebo mm @ 0wk
NCT03030222 · Phase 4 · registry result, not featured evidence
44.1 vs 44 placebo mm @ 1wk
NCT03030222 · Phase 4 · registry result, not featured evidence
44.1 vs 44.1 placebo mm @ 2wk
NCT03030222 · Phase 4 · registry result, not featured evidence
44.1 vs 44.2 placebo mm @ 3wk
NCT03030222 · Phase 4 · registry result, not featured evidence
44 vs 44.3 placebo mm @ 4wk
NCT03030222 · Phase 4 · registry result, not featured evidence
44 vs 44.4 placebo mm @ 5wk
NCT03030222 · Phase 4 · registry result, not featured evidence
44 vs 44.6 placebo mm @ 6wk
NCT03030222 · Phase 4 · registry result, not featured evidence
43.8 vs 44.7 placebo mm @ 7wk
NCT03030222 · Phase 4 · registry result, not featured evidence
43.7 vs 44.8 placebo mm @ 8wk
NCT03030222 · Phase 4 · registry result, not featured evidence
43.6 vs 44.9 placebo mm @ 9wk
NCT03030222 · Phase 4 · registry result, not featured evidence
43.4 vs 44.9 placebo mm @ 10wk
NCT03030222 · Phase 4 · registry result, not featured evidence
43.3 vs 44.9 placebo mm @ 11wk
NCT03030222 · Phase 4 · registry result, not featured evidence
43.1 vs 44.9 placebo mm @ 12wk
NCT03030222 · Phase 4 · registry result, not featured evidence
Pulmonary Artery Pressure 29.3 vs 31.1 placebo mm @ 12wk
absolute change · mm
NCT03030222 · Phase 4 · registry result, not featured evidence
show 13 more results
30.1 vs 30.1 placebo mm @ 0wk
NCT03030222 · Phase 4 · registry result, not featured evidence
30.1 vs 30.2 placebo mm @ 1wk
NCT03030222 · Phase 4 · registry result, not featured evidence
30.1 vs 30.4 placebo mm @ 2wk
NCT03030222 · Phase 4 · registry result, not featured evidence
30 vs 30.5 placebo mm @ 3wk
NCT03030222 · Phase 4 · registry result, not featured evidence
30 vs 30.7 placebo mm @ 4wk
NCT03030222 · Phase 4 · registry result, not featured evidence
30 vs 30.8 placebo mm @ 5wk
NCT03030222 · Phase 4 · registry result, not featured evidence
30 vs 30.9 placebo mm @ 6wk
NCT03030222 · Phase 4 · registry result, not featured evidence
29.9 vs 31 placebo mm @ 7wk
NCT03030222 · Phase 4 · registry result, not featured evidence
29.9 vs 31.1 placebo mm @ 8wk
NCT03030222 · Phase 4 · registry result, not featured evidence
29.8 vs 31.1 placebo mm @ 9wk
NCT03030222 · Phase 4 · registry result, not featured evidence
29.6 vs 31.1 placebo mm @ 10wk
NCT03030222 · Phase 4 · registry result, not featured evidence
29.5 vs 31.1 placebo mm @ 11wk
NCT03030222 · Phase 4 · registry result, not featured evidence
29.3 vs 31.1 placebo mm @ 12wk
NCT03030222 · Phase 4 · registry result, not featured evidence
KCCQ-OSS 5 Point Improvement 39.4% (n=33) vs 46.9% (n=32) placebo @ 6wk
event count · % of participants
KCCQ-OS score increase >/= 5 points (6 weeks)
NCT03030222 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted

+ 24 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · Empagliflozin's landscape